AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection

1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...

Read more →

CADTH launches consultation on real world evidence reporting guidance

10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...

Read more →

Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients

10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...

Read more →

Vabysmo (faricimab) receives positive CADTH recommendation for the treatment of diabetic macular oedema in adults

3 November 2022 - This CADTH recommendation is the latest step towards public access to Vabysmo (faricimab) for the estimated 60,000 ...

Read more →

New PMPRB guidelines proposed for assessing prices of patented medicines sold in Canada

4 November 2022 - Controversial amendments to the Patented Medicines Regulations changing the basket of comparator countries considered by the ...

Read more →

PMPRB finds ultra-rare drug Procysbi is excessively priced

26 October 2022 - On 1 September 2022, a Panel of the Patented Medicine Prices Review Board issued a decision that ...

Read more →

Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy

21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...

Read more →

Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss

17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited ...

Read more →

Medical industry advocates urge Ontario to offer cheaper versions of prescription medications

11 October 2022 - Medical industry advocates are urging the Ontario government to offer cheaper versions of certain prescription medications ...

Read more →

Federal drug price watchdog consulting public on proposed changes to its pricing guidelines

7 October 2022 - The PMPRB's guidelines explain how its staff monitor and review patented medicine prices to ensure they are ...

Read more →

Tecentriq (atezolizumab) receives CADTH reimbursement recommendations for the adjuvant treatment of early-stage non-small-cell lung cancer and the treatment of extensive stage small cell lung cancer

5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...

Read more →

CADTH recommendation to not reimburse new treatment a failure for people living with schizophrenia

21 September 2022 - The Schizophrenia Society of Canada is joined by the schizophrenia community across Canada in its disappointment with ...

Read more →

Novartis and the pan-Canadian Pharmaceutical Alliance conclude negotiations for Luxturna, a gene therapy for previously untreatable inherited vision loss

20 September 2022 - Novartis Pharmaceuticals Canada and the pan Canadian Pharmaceutical Alliance have successfully concluded negotiations for Luxturna (voretigene neparvovec), ...

Read more →

CADTH partners with international health technology assessment bodies to boost collaboration on shared challenges

6 September 2022 - Six health technology assessment bodies from three continents will join forces to collaborate on a range of ...

Read more →